Boston Scientific Surges 5% After Blowout Q1

• Boston Scientific Corporation (NYSE:BSX) reported an earnings per share (EPS) of $0.75, surpassing the estimated $0.67.
• The company's revenue for the quarter was approximately $4.66 billion, exceeding the estimated $4.57 billion.
• Boston Scientific has increased its annual profit forecast for 2025 following a significant surge in its stock price.

Boston Scientific Corporation (NYSE:BSX) is a leading medical device company that develops and manufactures a wide range of products used in interventional medical specialties. The company operates in the Zacks Medical - Products industry and competes with other major players in the sector. On April 23, 2025, Boston Scientific reported impressive financial results for the first quarter, which have positively impacted its stock performance.

Boston Scientific reported earnings per share (EPS) of $0.75, surpassing the estimated $0.67. This represents an 11.94% earnings surprise, as highlighted by Zacks. The company has consistently outperformed consensus EPS estimates over the past four quarters, demonstrating strong financial performance. In the previous quarter, BSX also exceeded expectations with an EPS of $0.70 against an anticipated $0.65.

The company's revenue for the quarter was approximately $4.66 billion, exceeding the estimated $4.57 billion. This marks a 2.31% revenue surprise, as noted by Zacks. Compared to the same period last year, when revenue was $3.86 billion, Boston Scientific has shown significant growth. The company has consistently surpassed consensus revenue estimates in the last four quarters, driven by robust sales of its heart devices.

Boston Scientific's strong financial performance has led to an increase in its annual profit forecast for 2025. The company's stock experienced a significant surge following the release of its first-quarter results, which exceeded analysts' expectations. This positive performance has contributed to the upward movement in the company's stock price.

In addition to its financial achievements, Boston Scientific announced a notable change in its executive team, with the retirement of its Chief Financial Officer. The company maintains a debt-to-equity ratio of approximately 0.51, indicating a moderate level of debt relative to its equity. Its current ratio stands at about 1.08, suggesting a reasonable level of short-term financial health.

• Citigroup reaffirms "Outperform" rating for NYSE:BSX, indicating a positive outlook despite a slight decline in its latest trading session.
• BSX shares have outperformed the Medical sector and the S&P 500 over the past month, despite a 5.44% decrease.
• Anticipated earnings report on April 23, 2025, expects an EPS of $0.67 and revenue of $4.56 billion, highlighting significant year-over-year growth.

Boston Scientific Corporation, listed on the NYSE under the symbol BSX, is a prominent player in the medical device industry. The company specializes in developing and manufacturing a wide range of medical solutions, including devices for cardiology, endoscopy, and urology. Boston Scientific competes with other major medical device companies like Medtronic and Johnson & Johnson.

On April 18, 2025, Citigroup reaffirmed its "Outperform" rating for BSX, with the stock priced at $95.12. This rating suggests that Citigroup expects BSX to perform better than the overall market. Despite this positive outlook, BSX experienced a slight decline of 0.14% in its latest trading session, closing at $95.12. This contrasts with the S&P 500's gain of 0.13%.

Over the past month, BSX shares have decreased by 5.44%. However, this performance is relatively strong compared to the Medical sector's loss of 8.46% and the S&P 500's decline of 6.3%. Investors are eagerly anticipating Boston Scientific's upcoming earnings report on April 23, 2025. The company is expected to report an EPS of $0.67, a 19.64% increase from the same quarter last year.

Revenue for Boston Scientific is anticipated to reach $4.56 billion, marking an 18.2% rise compared to the previous year. The stock has fluctuated between $94.70 and $96.06 today, with a 52-week high of $107.17 and a low of $66.80. BSX's market capitalization is approximately $140.7 billion, with a trading volume of 6.67 million shares.

Needham raised its rating on Boston Scientific (NYSE:BSX) from Hold to Buy, setting a new price target of $113, citing improving fundamentals and a more favorable competitive landscape.

The firm now sees the threat from pulsed field ablation (PFA) rivals as less significant than previously thought, based on feedback from its latest survey of electrophysiologists. In addition, Boston Scientific’s WATCHMAN device may experience near-term sales upside from more frequent use alongside other procedures, with longer-term gains expected from the upcoming CHAMPION trial results, due in the first half of 2026.

Needham also highlighted the company’s recent acquisitions—Bolt Medical and SoniVie—as potential catalysts. Bolt’s intravascular lithotripsy (IVL) system recently received clearance for above-the-knee procedures, setting the stage for growth contributions beginning in 2025. Following a pullback from all-time highs, Needham believes Boston Scientific’s valuation is now more attractive, reinforcing the upgrade to Buy.

Boston Scientific Corporation, trading on the NYSE under the symbol BSX, is a leader in medical technology. The company is known for its innovative solutions that improve patient health worldwide. It offers a range of high-performance products for complex diseases across various medical fields. Boston Scientific competes with other major players in the medical technology industry, such as Medtronic and Johnson & Johnson.

Boston Scientific is set to participate in TD Cowen's 45th Annual Health Care Conference on March 4, 2025. Key executives, including Dan Brennan, Art Butcher, and Dr. Kenneth Stein, will engage in a 30-minute fireside chat. This session will be available via a live webcast, with a replay accessible shortly after the event. This participation highlights the company's commitment to engaging with investors and stakeholders.

On February 19, 2025, Dan Brennan, the Executive Vice President and CFO, sold 67,333 shares of Boston Scientific stock at approximately $105.24 each. After this transaction, he still holds 225,808 shares. This sale is part of routine financial management and does not necessarily indicate a lack of confidence in the company's future.

Currently, BSX stock is priced at $104.86, reflecting a decrease of 0.81, or -0.77%. The stock has fluctuated between $104.35 and $105.46 today. Over the past year, BSX has seen a high of $107.17 and a low of $65.52. The company's market capitalization is approximately $154.5 billion, indicating its significant presence in the market.

Today's trading volume for BSX is 2,217,759 shares, showing active investor interest. The stock's performance and trading activity are important indicators for investors. As Boston Scientific continues to innovate and expand its offerings, its participation in industry events like the TD Cowen conference is crucial for maintaining investor confidence and market presence.

• Boston Scientific Corporation (NYSE:BSX) sells 14,010 shares by Executive VP, indicating potential insights on the company's future.
• The acquisition of Intera Oncology® Inc. aims to enhance Boston Scientific's interventional oncology offerings, focusing on liver-dominant metastases in colorectal cancer patients.
• Financial indicators such as a price-to-earnings (P/E) ratio of 73.47 and a debt-to-equity ratio of 0.53 reflect investor expectations and the company's financial health.

Boston Scientific Corporation (NYSE:BSX) is a global leader in the development and manufacturing of medical devices. The company focuses on providing innovative solutions across various medical fields, including interventional cardiology, endoscopy, and neuromodulation. Boston Scientific competes with other major players in the medical device industry, such as Medtronic and Johnson & Johnson.

On November 25, 2024, Butcher Arthur C, Executive Vice President and Group President for MedSurg & APAC at Boston Scientific, sold 14,010 shares of the company's common stock at approximately $89.27 each. This transaction leaves him with 978 shares. Such insider transactions can sometimes provide insights into the executive's perspective on the company's future performance.

Boston Scientific recently announced a definitive agreement to acquire Intera Oncology® Inc., a move aimed at expanding its interventional oncology offerings. Intera Oncology provides the Intera 3000 Hepatic Artery Infusion Pump and the chemotherapy drug floxuridine, both FDA-approved. This acquisition is expected to enhance Boston Scientific's capabilities in treating liver-dominant metastases, a condition affecting many colorectal cancer patients.

The acquisition aligns with Boston Scientific's strategic goals, as approximately 1.4 million people in the U.S. live with primary colorectal cancer, with over 150,000 new cases diagnosed annually. For nearly 25% of these patients, the cancer spreads to the liver. By integrating Intera Oncology's products, Boston Scientific aims to offer more effective treatments for these patients.

Financially, Boston Scientific has a price-to-earnings (P/E) ratio of 73.47, indicating high investor expectations for future growth. The company's price-to-sales ratio is 8.27, and its enterprise value to sales ratio is 8.82. With a debt-to-equity ratio of 0.53, Boston Scientific maintains a moderate level of debt, while a current ratio of 1.48 suggests adequate liquidity to cover short-term liabilities.

• Boston Scientific (NYSE:BSX) sees a price target increase from Citigroup despite a recent share price decline.
• The company reports a 7% drop in net income but exceeds revenue forecasts with a 19% surge, driven by cardiovascular product sales.
• Boston Scientific's adjusted EPS of $0.63 beats projections, underscoring effective core operation management.

Boston Scientific (NYSE:BSX) is a leading medical device company known for its innovative products in the cardiovascular, endoscopy, and urology fields. The company competes with other major players like Medtronic and Abbott Laboratories. On October 24, 2024, Citigroup maintained its "Buy" rating for BSX, reflecting confidence in the company's future prospects. At that time, the stock was priced at $87.45.

Citigroup's decision to raise the price target for Boston Scientific from $92 to $98 indicates optimism about the company's potential growth. This comes despite the recent decline in BSX's share price following its third-quarter financial results. The stock experienced a decrease of 0.64%, or $0.56, on the day of the announcement, fluctuating between $83.27 and $87.58.

Boston Scientific's third-quarter results revealed a 7% year-over-year drop in net income to $469 million, missing the $543 million consensus estimate. The GAAP earnings per share (EPS) was $0.32, below the expected range of $0.36 to $0.38. However, the adjusted EPS of $0.63 exceeded projections, showcasing the company's ability to manage its core operations effectively.

Despite the profit shortfall, Boston Scientific's revenue surged 19% to $4.21 billion, surpassing forecasts. This growth was largely driven by a 25% increase in sales of its cardiovascular products, which reached $2.73 billion. The strong performance in this segment highlights the company's competitive edge in the medical device industry.

Boston Scientific's market capitalization is approximately $128.78 billion, with a trading volume of 18.02 million shares. Over the past year, the stock has reached a high of $88.79 and a low of $49.15. The company's mixed update on its full-year forecast suggests a cautious yet optimistic outlook for the future.